Model-informed drug development for immune checkpoint inhibitors
10.16438/j.0513-4870.2020-1610
- VernacularTitle:模型引导下免疫检查点抑制剂的研发
- Author:
Guan-hao ZHENG
1
,
2
;
Chen-yu WANG
3
;
Zheng JIAO
3
Author Information
1. Shenzhen Hospital, Southern Medical University, Shenzhen 518000, China
2. Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai 200030, China
3. Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai 200030, China
- Publication Type:Research Article
- Keywords:
model-informed drug development;
modeling;
simulation;
pharmacometrics;
immune checkpoint inhibitor;
pembrolizumab
- From:
Acta Pharmaceutica Sinica
2021;56(3):734-742
- CountryChina
- Language:Chinese
-
Abstract:
With a deepening understanding of cancer treatment, immune checkpoint inhibitors are recognized widely as a novel fundamental remedy for various malignancies with effectiveness and safety. With the development of pharmacometrics, model-informed drug development (MIDD) has emerged to accelerate the process of clinical research for new drugs and improve the accuracy of decision-making in new drug research, especially for immune checkpoint inhibitors. As a typical illustration, the research development of pembrolizumab is presented in this review to highlight the application of MIDD, which may provide a reference for the development of other new antitumor drugs.
